Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 2/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9826810 | 0.81 | TSHR (0.42) | TSHRGAAALDH1A1KDM4EDGAT1 | |
| SCHEMBL25288451 | 0.80 | ACLY (0.39) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL28235073 | 0.78 | ACLY (0.38) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL10891188 | 0.77 | POLB (0.42) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL11056460 | 0.77 | TSHR (0.40) | TSHRKCNN4ALDH1A1KDM4EDGAT1 | |
| SCHEMBL2069147 | 0.76 | ACLY (0.50) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL1583583 | 0.75 | — | — | |
| SCHEMBL3608850 | 0.75 | — | — | |
| SCHEMBL8656249 | 0.75 | TSHR (0.59) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL3322447 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344597-B2 | Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-07-01 | — | — | US | disclosed |
| CN-112236424-B | Alkoxy-substituted pyridinyl derivatives | 爱杜西亚药品有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20050059611-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-03-17 | — | — | US | disclosed |
| US-6821960-B2 | Glucagon antagonists/inverse agonists | NOYO NORDISK PHARMACEUTICALS, INC. | 2004-11-23 | — | — | US | disclosed |
| EP-1345891-A1 | GLUCAGON ANTAGONIST/INVERSE AGONIST | Novo Nordisk A/S (DK) | 2003-09-24 | — | — | EP | disclosed |
| US-20030027849-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-02-06 | — | — | US | disclosed |
| WO-2002040446-A1 | GLUCAGON ANTAGONIST/INVERSE AGONIST | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040446-A1 | GLUCAGON ANTAGONIST/INVERSE AGONIST | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
| EP-0220409-B1 | GEM-DIHALO AND TETRAHALO-1,12-DIAMINO-4,9-DIAZA-DODECANES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-11-27 | — | — | EP | disclosed |
| EP-0215319-B1 | GEM-DIHALO-1,8-DIAMINO-4-AZA-OCTANES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-16 | — | — | EP | disclosed |
| US-4914240-A | PROTECTING DIHALO BUTANEDIOL, REACTING WITH POTASSIUM PHTHALIMINDE, DEPROTECTING; MULTISTEP | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-03 | — | — | US | disclosed |
| US-4851448-A | Gem-dihalo-1,8-diamino-4-aza-octanes | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4778926-A | ANTITUMOR AND ANTIGROWTH AGENTS; CHEMICAL INTERMEDIATES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-10-18 | — | — | US | disclosed |
| US-4719313-A | ANTITUMOR | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-01-12 | — | — | US | disclosed |
| US-4695654-A | ANTITUMOR AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0220409-A2 | Gem-dihalo and tetrahalo-1,12-diamino-4,9-diaza-dodecanes | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-05-06 | — | — | EP | disclosed |
| EP-0215319-A2 | Gem-dihalo-1,8-diamino-4-aza-octanes | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344597-B2 | Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis | LPAR1, LPAR3, LPAR2 | HMGCR 1467/4885CHRM1 74/4885TBXA2R 85/4885 |
| US-20050059611-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | HMGCR 1020/4885CHRM1 1171/4885TBXA2R 183/4885 |
| US-20030027849-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | HMGCR 1020/4885CHRM1 1171/4885TBXA2R 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.